The second startup problem has to do with risk. And in a market where we have had this fall of the genomics bubble which has brought down valuations of public biotechs which therefore has brought down the valuations of the private biotechs seeking privat...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
